Ionis

#ACAAI2026 brings together allergists and immunologists working to advance care for people living with hereditary angioedema (#HAE). We look forward to connecting and sharing insights on our RNA-targeted science. Learn more: ionis.com/science-and-innova… #IONISinnovation

Save the date for our Q3 2026 earnings webcast. Register now and tune in live on November 9 at 9:00 am ET: bit.ly/4zkAERR $IONS

Today, with our partner @Roche, we announced new positive data from a Phase 3 study for an investigational medicine for the treatment of IgA nephropathy (IgAN). Read more: bit.ly/4z7vyZi $IONS

Today, with our partner @GSK, we announced the FDA approval for a first-of-its kind medicine for the treatment of chronic hepatitis B (CHB) in the U.S. Learn more: bit.ly/3UyByeq $IONS

The CHMP in the European Union recommended the approval of Ionis’ and Sobi’s treatment for severe hypertriglyceridemia (sHTG). Read more: bit.ly/4B9cRFX $IONS

Today, with our partner @Roche, we announced positive interim results from a Phase 3 study for an investigational medicine for the treatment of IgA nephropathy (IgAN). Read more: ir.ionis.com/news-releases/n… $IONS

Today marks an important step forward for the FUS-ALS community and for our shared goal of advancing a new treatment option for people living with this rare, rapidly progressive form of genetic #ALS. Read more: bit.ly/3V5Un8O $IONS

Today w/ partner Otsuka we announced positive topline results from the Ph3 FUSION study evaluating an investigational RNA-targeted medicine for people w/ amyotrophic lateral sclerosis (#ALS) caused by mutations in the fused in sarcoma (FUS) gene: ir.ionis.com/news-releases/n… $IONS

Academics, don’t miss this opportunity to share your cutting-edge insights in RNA-targeted technology. Submit your abstract now through October 1st for a chance to contribute to the conversation, or register to attend by November 10th: bit.ly/4javGlm #RNAbench2bedside

Today, with our partner @Novartis , we announced topline results from the Phase 3 Lp(a)HORIZON clinical trial in patients with cardiovascular disease and elevated levels of Lp(a). Learn more: ir.ionis.com/news-releases/n…

Today, the U.S. FDA approved our medicine for Alexander disease (#AxD) marking the start of a new chapter for people and families living with this ultra-rare disease. Hear more from our CEO, Brett P. Monia, PhD. $IONS

Ionis will host an investor webcast to discuss the U.S. FDA approval of our medicine for Alexander disease (#AxD). Access a link to the webcast: app.webinar.net/Pjnb9l1LZ0D

BREAKING NEWS: We’re proud to share that we have received U.S. FDA approval for ZANVASTRO™ (zilganersen), an important advance for patients and a meaningful milestone in our work to address serious neurological diseases. Read more: ir.ionis.com/news-releases/n… $IONS

Hear from Ionis’ Sam Tsimikas (@Lpa_Doc) about the four emerging trends that are poised to shape future severe hypertriglyceridemia (#sHTG) management: bit.ly/4gF4J6r #IONISinnovation

Learn more about new data presented at #ESCCongress from our open-label extension study of our treatment for severe hypertriglyceridemia (#sHTG): bit.ly/3SgSwwZ

Next week, we are sharing new data on the management of severe hypertriglyceridemia (#sHTG) at #ESCCongress. Read more: bit.ly/3U88RV7

We are honored that our medicine for familial chylomicronemia syndrome (FCS) has been nominated for the #PrixGalien USA award for Best Biotechnology Product. Read more: prn.to/3RJGv2R

Today we reported Q2 2026 financial results. Read more and tune in live to the webcast today at 8:30 AM ET to hear our second quarter highlights: bit.ly/4gXSFzb $IONS

Save the date for our Q2 2026 earnings webcast. Register now and tune in live on July 29 at 8:30 am ET: bit.ly/4wDN85h $IONS

Today, our partner @Biogen shared data at #AAIC26 from the Phase 2 CELIA study evaluating our investigational antisense oligonucleotide (ASO) therapy targeting tau in individuals with early Alzheimer’s disease. Read more: bit.ly/4f9Podu $IONS #AlzheimersDisease